Challenges of drug resistance in the management of pancreatic cancer.
about
Structure and function of human DnaJ homologue subfamily a member 1 (DNAJA1) and its relationship to pancreatic cancerRLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancerMechanistic evaluation of a novel small molecule targeting mitochondria in pancreatic cancer cellsApplication of concave microwells to pancreatic tumor spheroids enabling anticancer drug evaluation in a clinically relevant drug resistance modelDownregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTENAutophagy, Warburg, and Warburg reverse effects in human cancer.K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.Clusterin confers gemcitabine resistance in pancreatic cancerMicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal AdenocarcinomaBroad targeting of resistance to apoptosis in cancer.Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic modelDesigning of promiscuous inhibitors against pancreatic cancer cell lines.Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands.Recent studies of 5-fluorouracil resistance in pancreatic cancerInduction of pancreatic cancer cell apoptosis and enhancement of gemcitabine sensitivity by RAP80 siRNA.Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells.MIR506 induces autophagy-related cell death in pancreatic cancer cells by targeting the STAT3 pathway.Apoptosis and expression of the Bcl-2 family of proteins and P53 in human pancreatic ductal adenocarcinoma.Leptin-Notch axis impairs 5-fluorouracil effects on pancreatic cancer.
P2860
Q24336620-85572C50-E451-4F8D-A4AE-3EA5F3BA00E2Q28482104-3DDDBA00-8804-464F-BC4E-2E0078A58A1EQ28485201-C1C63E8A-380B-4309-B7D6-F0178C7FDA02Q28533194-2A07D306-A76C-442E-A84C-9E6BA8E3E91EQ33623176-5B0013E1-1FC2-416D-AEFA-BF54E2A62814Q34092128-7011FEFA-E49A-4460-BC16-1498A2439EA3Q34406302-3AF26B9E-0AFE-4C9E-8567-F4EC91E29792Q35061171-D6FE569C-F288-41E8-AF95-85F4BE2B77FAQ35852437-0D517C7F-8CA1-41E3-BC83-53324E2B1667Q36483749-ED78F10A-9C85-4F77-AEE9-86487A02547CQ37170729-81A179E8-636E-4B60-8882-A5C32378C759Q37700338-2341014A-02C2-42BC-8036-6F5AA6CE1607Q38024011-61B23C1F-9D1C-45A1-B2FA-9087AE732BB8Q38268619-226B2376-AE36-4B2D-A507-1332BA990B54Q39351203-FE6427BF-16C8-45E0-8E7F-3D0D1ABBDE04Q39398132-29AFA278-6AA1-4708-B224-8093261D80ABQ48857817-B75AE62B-15B3-4A8E-B3E3-F5B9864CF7DBQ51511748-514755A0-EE2F-46F5-B5F5-A4DF05B7D33FQ55282022-03929EDC-3444-4959-9253-5D8A8263D7D7
P2860
Challenges of drug resistance in the management of pancreatic cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Challenges of drug resistance in the management of pancreatic cancer.
@en
Challenges of drug resistance in the management of pancreatic cancer.
@nl
type
label
Challenges of drug resistance in the management of pancreatic cancer.
@en
Challenges of drug resistance in the management of pancreatic cancer.
@nl
prefLabel
Challenges of drug resistance in the management of pancreatic cancer.
@en
Challenges of drug resistance in the management of pancreatic cancer.
@nl
P2093
P2860
P356
P1476
Challenges of drug resistance in the management of pancreatic cancer.
@en
P2093
Martin Clynes
Naomi Walsh
Ray McDermott
Rizwan Sheikh
Robert O'Connor
P2860
P304
P356
10.1586/ERA.10.148
P577
2010-10-01T00:00:00Z